Keyphrases
Colorectal Cancer
87%
Metastatic Colorectal Cancer (mCRC)
54%
Overall Survival
43%
Phase II Study
40%
Chemotherapy
31%
Progression-free Survival
30%
Irinotecan
29%
Pembrolizumab
27%
Oxaliplatin
25%
Targeted Therapy
25%
Programmed Death-ligand 1 (PD-L1)
25%
Capecitabine
25%
Microsatellite Instability-high (MSI-H)
23%
5-fluorouracil (5-FU)
22%
Leucovorin
21%
Hazard Ratio
19%
Liposomal Irinotecan
18%
Adverse Events
18%
Immune Checkpoint Inhibitors
18%
Tolerability
18%
Next-generation Sequencing
17%
Adjuvant Chemotherapy
16%
Gemcitabine
16%
Tumor
16%
Regorafenib
15%
National Cancer Database
15%
Previously Treated
15%
Chemoradiation
15%
Wild-type KRAS
14%
Phase II Trial
14%
Cancer Patients
14%
Confidence Interval
13%
Bevacizumab
13%
Overall Response Rate
13%
Human Epidermal Growth Factor Receptor 2 (HER2)
13%
Objective Response Rate
12%
Microsatellites
12%
Combined Analysis
12%
Dose Optimization
12%
Metastatic Pancreatic Cancer
12%
Related Rates
12%
Selective Internal Radiation Therapy
12%
Age-related
12%
Treatment Refractory
12%
Dose Level
12%
Median Progression-free Survival
12%
Locally Advanced
12%
Partial Response
11%
Maximum Tolerated Dose
11%
Treatment-related Adverse Events
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
63%
Metastatic Colorectal Cancer
61%
Colorectal Carcinoma
51%
Progression Free Survival
44%
Irinotecan
43%
Adverse Event
39%
Overall Survival
36%
Neoplasm
29%
Diseases
29%
Malignant Neoplasm
28%
Oxaliplatin
26%
Capecitabine
25%
Pancreas Cancer
25%
Adenocarcinoma
22%
Fluorouracil
21%
Folinic Acid
21%
Bevacizumab
20%
Pembrolizumab
18%
Chemoradiation Therapy
18%
Tolerability
17%
Gemcitabine
16%
Rectum Cancer
14%
Pharmacokinetics
14%
Pancreas Adenocarcinoma
13%
Phase II Trials
12%
Immune Checkpoint Inhibitor
12%
Liver Metastasis
11%
Diarrhea
11%
Maximum Tolerated Dose
10%
Clinical Trial
10%
Regorafenib
9%
Primary Tumor
9%
Disease Exacerbation
9%
Neutropenia
8%
Immunotherapy
8%
Trastuzumab
8%
Monotherapy
8%
Solid Malignant Neoplasm
8%
Colon Carcinoma
8%
Side Effect
7%
Survival Rate
6%
Epidermal Growth Factor Receptor
6%
Recurrence Free Survival
6%
Randomized Controlled Trial
6%
Circulating Tumor DNA
6%
Axalimogene Filolisbac
6%
Squamous Cell Carcinoma
6%
Pralatrexate
6%
Anus Cancer
6%
Programmed Death 1 Ligand 1
6%
Medicine and Dentistry
Colorectal Carcinoma
100%
Malignant Neoplasm
52%
Overall Survival
46%
Metastatic Colorectal Cancer
41%
Diseases
35%
Neoplasm
29%
Progression Free Survival
29%
Immunotherapy
28%
Pembrolizumab
27%
Targeted Therapy
24%
Cancer
24%
Chemoradiotherapy
23%
Rectum Cancer
23%
Immune Checkpoint Inhibitor
18%
Colon Carcinoma
18%
Adverse Event
18%
Hazard Ratio
17%
Adjuvant Chemotherapy
15%
Recurrent Disease
13%
Radiation Therapy
12%
Capecitabine
12%
Bevacizumab
12%
Immunity
12%
Oxaliplatin
12%
Primary Tumor
11%
Next Generation Sequencing
11%
Adenocarcinoma
11%
Liver Metastasis
11%
Microsatellite Instability
11%
Clinical Trial
10%
Diagnosis
9%
Colon
9%
Base
9%
Patient Selection
8%
DNA Mismatch Repair
8%
Pancreas Adenocarcinoma
8%
Randomized Controlled Trial
8%
Trastuzumab
8%
Regorafenib
8%
Survival Rate
7%
Gastrointestinal Cancer
7%
FOLFOX
7%
Disease Exacerbation
7%
Oncologist
6%
Metastatic Carcinoma
6%
Biological Marker
6%
Pralatrexate
6%
Squamous Cell Carcinoma
6%
Hypochromic Anemia
6%
Recurrence Free Survival
6%